Settle Genetics' bladder cancer
therapy Padcev saw $34.5 million in sales in its first quarter on the market,
well above industry expectations. Padcev, which received FDA approval in
December 2019, remains not covered or unlisted for 55% of all covered lives
under the pharmacy benefit. The drug holds covered (with and without prior
authorization and/or step therapy) for 35% of lives.
SOURCE: MMIT Analytics, as
of 5/6/20
No comments:
Post a Comment